Cullinan Therapeutics, Inc. SEC filings CGEM
Cullinan Therapeutics, Inc. has 466 filings in SEC EDGAR's recent list, going back to Nov 2, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| UPLOAD | Letter from the SEC | May 20, 2024 | — |
| EFFECT | Filing | May 18, 2023 | — |
| CORRESP | Letter to the SEC | May 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 17, 2023 | — |
| CORRESP | Letter to the SEC | Mar 9, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2023 | — |
| SEC STAFF LETTER | Filing | Jan 7, 2021 | — |
| EFFECT | Filing | Jan 7, 2021 | — |
| CERT | Filing | Jan 7, 2021 | — |
| CORRESP | Letter to the SEC | Jan 6, 2021 | — |
| 8-A12B | Filing | Jan 6, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2021 | — |
| CORRESP | Letter to the SEC | Jan 4, 2021 | — |
| CORRESP | Letter to the SEC | Jan 4, 2021 | — |
| CORRESP | Letter to the SEC | Dec 18, 2020 | — |
| CORRESP | Letter to the SEC | Dec 18, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2020 | — |
| DRSLTR | Filing | Dec 9, 2020 | — |
| DRS/A | Filing | Dec 9, 2020 | — |
| SEC STAFF LETTER | Filing | Dec 3, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 1, 2020 | — |
| DRS | Filing | Nov 2, 2020 | — |
Showing 24 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CGEM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1789972
- Former names
- Cullinan Oncology, Inc. (until Apr 2, 2024); Cullinan Management, Inc. (until Feb 22, 2021); Cullinan Oncology, LLC (until Jan 6, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.